Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment

Dopamine agonists (DAs) have demonstrated efficacy for the treatment of Parkinson’s disease (PD) but are limited by adverse effects (AEs). DAs can vary considerably in their receptor subtype selectivity and affinity, chemical composition, receptor occupancy, and intrinsic activity on the receptor. M...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Stuart H. Isaacson, Robert A. Hauser, Rajesh Pahwa, David Gray, Sridhar Duvvuri
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Elsevier 2023-01-01
Ráidu:	Clinical Parkinsonism & Related Disorders
Fáttát:	Parkinson’s disease Dopamine agonists D1 receptors D2 receptors Partial agonism Dopamine receptor selectivity
Liŋkkat:	http://www.sciencedirect.com/science/article/pii/S2590112523000300
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!